Abstract
Lumsden JM, Urv TK. The Rare Diseases Clinical Research Network: a model for clinical trial readiness. Therapeutic Advances in Rare Disease. 2023;4. doi:10.1177/26330040231219272
In the above-mentioned article, the number of FDA-approved treatments for rare diseases has been updated to ten in the following text.
In the result section of the abstract, the sentence “They have produced 2763 high-quality publications that have been cited more than 100,000 times, expanded international networks, and contributed scientifically to eight FDA-approved treatments for rare diseases” should be read as “They have produced 2763 high-quality publications that have been cited more than 100,000 times, expanded international networks, and contributed scientifically to ten FDA-approved treatments for rare diseases.”
In the plain language summary section, the sentence “To date the RDCRN has been involved in work that has led to eight treatments being approved by the Food and Drug Administration (FDA).” should be read as “To date the RDCRN has been involved in work that has led to ten treatments being approved by the Food and Drug Administration (FDA).”
In the discussion section, the sentence “Findings from the RDCRN have contributed to the approval of eight treatments for rare diseases by the FDA.” should be read as “Findings from the RDCRN have contributed to the approval of ten treatments for rare diseases by the FDA.”
The correction has been updated in the online version.